To include your compound in the COVID-19 Resource Center, submit it here.

Rhucin: SPA received

Pharming received an SPA from FDA after amending the protocol for an ongoing, double-blind, placebo-controlled Phase III trial evaluating IV Rhucin. In

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE